Small-Cap ProQR Therapeutics Secures Funding From Eli Lilly On Early Trial Success - ProQR Therapeutics (

ProQR reported positive AX-0810 Phase 1 data and raised $50 million, with Eli Lilly joining a concurrent share purchase.

Raccontata dabenzinga.com